Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod Combinations in Rheumatoid Arthritis
NCT05626348Phase 4Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of iguratimod in rheumatoid arthritis (RA) (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Percentage of patients who achieve clinical remission using DAS28 at 24 weeks. Started Dec 2021; status: recruiting.
02
Drugs
iguratimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05626348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626348.